Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 11/20 | 0.61 |
| ▸ | RAB9A | P51151 | 11/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | PKM | P14618 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325737 | 0.83 | TLR9 (0.72) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL20019429 | 0.82 | RAB9A (0.63) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL18807110 | 0.80 | RAB9A (0.60) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL26578936 | 0.79 | RAB9A (0.63) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4780900 | 0.79 | RAB9A (0.76) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL6389879 | 0.77 | RAB9A (0.97) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL12848498 | 0.75 | RAB9A (0.68) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL23173221 | 0.74 | KDM4E (0.60) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL18807109 | 0.74 | CASP3 (0.54) | TLR9NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4728826 | 0.74 | RAB9A (0.76) | TLR9NPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753325-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-31 | — | — | US | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, HAVCR2, EIF2AK2 | TLR9 3015/4885NPC1 243/4885RAB9A 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.